Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Vera Therapeutics (NASDAQ: VERA) reported key developments in Q3 2024, highlighting positive 96-week eGFR stabilization data from the ORIGIN Phase 2b trial of atacicept in IgAN. The company completed enrollment for the pivotal Phase 3 ORIGIN 3 trial, with topline data expected in Q2 2025. Vera reported a Q3 net loss of $46.6 million ($0.85 per share), compared to $20.1 million ($0.45 per share) in the previous year. The company strengthened its financial position with a $345 million equity offering and reported $353.3 million in cash and equivalents, which is expected to fund operations through potential approval and commercial launch of atacicept.
Vera Therapeutics (NASDAQ: VERA) ha riportato sviluppi chiave nel terzo trimestre del 2024, evidenziando dati positivi sulla stabilizzazione dell'eGFR a 96 settimane dallo studio ORIGIN di fase 2b su atacicept per l'IgAN. L'azienda ha completato l'arruolamento per lo studio cruciale di fase 3 ORIGIN 3, con dati preliminari attesi nel secondo trimestre del 2025. Vera ha registrato una perdita netta nel terzo trimestre di 46,6 milioni di dollari (0,85 dollari per azione), rispetto ai 20,1 milioni di dollari (0,45 dollari per azione) dell'anno precedente. L'azienda ha rafforzato la sua posizione finanziaria con un'offerta di equity da 345 milioni di dollari e ha riportato 353,3 milioni di dollari in contante e equivalenti, che si prevede finanzieranno le operazioni fino all'approvazione e al lancio commerciale di atacicept.
Vera Therapeutics (NASDAQ: VERA) informó sobre desarrollos clave en el tercer trimestre de 2024, destacando datos positivos de estabilización de eGFR a 96 semanas del ensayo ORIGIN de fase 2b de atacicept en IgAN. La compañía completó la inscripción para el ensayo pivotal de fase 3 ORIGIN 3, con datos preliminares esperados para el segundo trimestre de 2025. Vera reportó una pérdida neta en el tercer trimestre de 46,6 millones de dólares (0,85 dólares por acción), en comparación con 20,1 millones de dólares (0,45 dólares por acción) del año anterior. La empresa fortaleció su posición financiera con una oferta de acciones de 345 millones de dólares y reportó 353,3 millones de dólares en efectivo y equivalentes, que se espera financien las operaciones hasta la aprobación y lanzamiento comercial de atacicept.
베라 테라퓨틱스 (NASDAQ: VERA)는 2024년 3분기에 주요 개발 사항을 보고하며 IgAN의 atacicept에 대한 ORIGIN 2b 단계 시험에서 96주 동안의 긍정적인 eGFR 안정화 데이터를 강조했습니다. 회사는 중추적인 3상 ORIGIN 3 시험에 대한 등록을 완료했으며, 주요 데이터는 2025년 2분기에 발표될 예정입니다. 베라는 3분기에 4660만 달러 (주당 0.85달러)의 순손실을 기록했으며, 이는 지난해 2010만 달러 (주당 0.45달러)와 비교됩니다. 회사는 3억 4500만 달러의 자본 출처로 재정적 위치를 강화했으며, 3억 5330만 달러의 현금 및 현금등가물을 보고했으며, 이는 atacicept의 승인 및 상업적 출시 전까지 운영을 지원할 것으로 예상됩니다.
Vera Therapeutics (NASDAQ: VERA) a rapporté des développements clés au troisième trimestre 2024, mettant en évidence des données positives de stabilisation de l'eGFR sur 96 semaines provenant de l'essai ORIGIN de phase 2b concernant l'atacicept dans l'IgAN. L'entreprise a terminé le recrutement pour l'essai pivot de phase 3 ORIGIN 3, avec des données préliminaires attendues au deuxième trimestre 2025. Vera a enregistré une perte nette de 46,6 millions de dollars (0,85 dollar par action) au troisième trimestre, par rapport à 20,1 millions de dollars (0,45 dollar par action) l'année précédente. L'entreprise a renforcé sa position financière avec une offre d'actions de 345 millions de dollars et a rapporté 353,3 millions de dollars en liquidités et équivalents, ce qui devrait financer ses opérations jusqu'à l'approbation potentielle et au lancement commercial de l'atacicept.
Vera Therapeutics (NASDAQ: VERA) berichtete über wichtige Entwicklungen im dritten Quartal 2024 und hob positive Stabilitätsdaten von 96 Wochen zur eGFR aus der ORIGIN Phase 2b-Studie von Atacicept bei IgAN hervor. Das Unternehmen hat die Rekrutierung für die entscheidende Phase 3 ORIGIN 3-Studie abgeschlossen, wobei die erwarteten Hauptdaten im zweiten Quartal 2025 veröffentlicht werden sollen. Vera meldete im dritten Quartal einen Nettverlust von 46,6 Millionen US-Dollar (0,85 US-Dollar pro Aktie), im Vergleich zu 20,1 Millionen US-Dollar (0,45 US-Dollar pro Aktie) im Vorjahr. Das Unternehmen stärkte seine finanzielle Position durch ein Eigenkapitalangebot über 345 Millionen US-Dollar und berichtete über 353,3 Millionen US-Dollar in Bargeld und Äquivalenten, wobei erwartet wird, dass dies die operationen bis zur potenziellen Genehmigung und kommerziellen Einführung von Atacicept finanziert.
- Completed enrollment in Phase 3 ORIGIN 3 trial with topline data expected Q2 2025
- Secured $345 million through equity offering
- Strong cash position of $353.3 million to fund operations through potential approval and launch
- Positive 96-week data from Phase 2b trial showing eGFR stabilization
- Increased net loss to $46.6 million in Q3 2024 vs $20.1 million in Q3 2023
- Higher cash burn with $95.5 million used in operations vs $67.0 million year-over-year
Insights
The Q3 results reveal significant financial developments for Vera Therapeutics. The company reported a
The increased cash burn rate, with
The completion of enrollment in the Phase 3 ORIGIN 3 trial marks a important milestone, with topline data expected in Q2 2025. The positive 96-week eGFR stabilization data from the Phase 2b trial, presented at ASN and published in JASN, strengthens atacicept's position as a potential best-in-class treatment for IgAN.
The expansion into multiple autoimmune kidney diseases through the PIONEER study demonstrates significant pipeline potential, targeting broader IgAN populations and conditions like membranous nephropathy and focal segmental glomerulosclerosis. This strategic expansion could substantially increase the drug's market potential and therapeutic impact.
- Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Society of Nephrology (JASN)
- Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN; topline data expected in Q2 2025
- Announced expanded atacicept development program in the broad IgAN population and in multiple autoimmune kidney diseases
- Completed an equity offering with gross proceeds of approximately
$345 million ahead of potential regulatory submission and commercial launch
BRISBANE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2024.
“We have made substantial progress advancing our clinical development program for atacicept in 2024. The positive data announced throughout the year, including the 96-week data from the ORIGIN trial presented in a late-breaking oral presentation at ASN’s Kidney Week 2024 along with simultaneous publication in JASN, have positioned atacicept as a potential best-in-class disease-modifying treatment option for patients with IgAN,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “Our mission is to bring safe and effective therapies to patients with high unmet needs. To this end, we are on track to deliver topline results of our Phase 3 pivotal trial in Q2 2025. In addition, we recently announced plans to expand the development of atacicept into the broad profile of IgAN and in multiple other autoimmune kidney diseases. The PIONEER study will evaluate the use of atacicept in treating IgAN patients that do not meet the inclusion/exclusion criteria of ORIGIN 3, as well as adjacent antibody-mediated autoimmune conditions such as membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). The PIONEER study recognizes that atacicept has true pipeline-in-a-product potential.”
Third Quarter and Recent Business Highlights
- Presented positive data showing eGFR stabilization at 96 weeks in ORIGIN Ph 2b clinical trial of atacicept in IgAN at the American Society of Nephrology Kidney Week 2024 and in manuscript form in JASN
- Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN
- Expanded atacicept development program in multiple autoimmune kidney diseases at its R&D Day in New York, joined by academic leaders Drs. Jonathan Barratt, Richard Lafayette, Brad Rovin
- Appointed industry veteran Matt Skelton as Executive Vice President, Commercial
- Completed a public equity offering of Class A common stock with gross proceeds totaling approximately
$345 million , further bolstering balance sheet ahead of potential regulatory submission and commercial launch
Major Upcoming Milestones
- Pivotal ORIGIN 3 trial on track to announce topline results in Q2 2025, with planned BLA submission to the U.S. FDA later in the year
- Plan to initiate the ORIGIN Extend study in Q4 2024, providing ORIGIN participants with extended access to atacicept and capturing longer-term safety and efficacy data
- Plan to initiate the PIONEER trial in 2025, which will evaluate the efficacy and safety of atacicept in expanded IgAN populations and anti-PLA2R and anti-nephrin podocytopathies
Financial Results for the Quarter Ended September 30, 2024
For the quarter ended September 30, 2024, the company reported a net loss of
During the nine months ended September 30, 2024, net cash used in operating activities was
Vera reported
About Atacicept
Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis.
The Phase 2b ORIGIN clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further reductions in Gd-IgA1, hematuria and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN.
Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA’s determination that, based on an assessment of data from the Phase 2b ORIGIN clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera believes atacicept is positioned for best-in-class potential, targeting B cells and plasma cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical studies across different indications.
About MAU868
MAU868, a potential first-in-class monoclonal antibody, has the potential to neutralize infection by blocking BKV virions from binding to host cells. BKV is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant. It is a leading cause of kidney transplant loss and transplant-associated morbidity; there are currently no approved treatments for BKV. Vera holds an exclusive worldwide license from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for the development and commercialization of MAU868 in all indications.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both BAFF and APRIL, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BKV, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com
Forward-looking Statements
Statements contained in this press release regarding Vera’s expectations regarding the offering are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Vera’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, Vera’s expectations regarding the completion of the offering. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
(unaudited) | (unaudited) | ||||||||||||||
Operating expenses: | |||||||||||||||
Research and development | $ | 40,314 | $ | 16,100 | $ | 92,825 | $ | 57,440 | |||||||
General and administrative | 9,487 | 5,656 | 25,431 | 17,544 | |||||||||||
Total operating expenses | 49,801 | 21,756 | 118,256 | 74,984 | |||||||||||
Loss from operations | (49,801 | ) | (21,756 | ) | (118,256 | ) | (74,984 | ) | |||||||
Other income, net | 3,169 | 1,652 | 9,533 | 4,649 | |||||||||||
Net loss | $ | (46,632 | ) | $ | (20,104 | ) | $ | (108,723 | ) | $ | (70,335 | ) | |||
Change in unrealized gains and losses on marketable securities | $ | 1,494 | $ | 67 | $ | 793 | $ | 149 | |||||||
Comprehensive loss | $ | (45,138 | ) | $ | (20,037 | ) | $ | (107,930 | ) | $ | (70,186 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.85 | ) | $ | (0.45 | ) | $ | (2.03 | ) | $ | (1.67 | ) | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 54,898,297 | 44,363,419 | 53,537,910 | 42,124,779 | |||||||||||
VERA THERAPEUTICS, INC. Condensed Balance Sheets (in thousands) | |||||||
September 30, | December 31, | ||||||
2024 | 2023 | ||||||
(unaudited) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash, cash equivalents and marketable securities | $ | 353,309 | $ | 160,716 | |||
Prepaid expenses and other current assets | 10,822 | 11,307 | |||||
Total current assets | 364,131 | 172,023 | |||||
Operating lease right-of-use assets | 3,921 | 2,949 | |||||
Other noncurrent assets | 508 | 574 | |||||
Total assets | $ | 368,560 | $ | 175,546 | |||
Liabilities and stockholders' equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 4,602 | $ | 11,118 | |||
Operating lease liabilities | 1,872 | 2,436 | |||||
Accrued expenses and other liabilities, current | 19,990 | 8,749 | |||||
Total current liabilities | 26,464 | 22,303 | |||||
Long-term debt | 50,470 | 49,877 | |||||
Operating lease liabilities, noncurrent | 2,568 | 1,395 | |||||
Accrued expenses and other liabilities, noncurrent | - | 286 | |||||
Total liabilities | 79,502 | 73,861 | |||||
Stockholders' equity | |||||||
Common stock | 55 | 44 | |||||
Additional paid-in-capital | 705,784 | 410,492 | |||||
Accumulated other comprehensive income | 1,044 | 251 | |||||
Accumulated deficit | (417,825 | ) | (309,102 | ) | |||
Total stockholders' equity | 289,058 | 101,685 | |||||
Total liabilities and stockholders' equity | $ | 368,560 | $ | 175,546 |
FAQ
What were Vera Therapeutics (VERA) Q3 2024 financial results?
When will Vera Therapeutics (VERA) release Phase 3 ORIGIN 3 trial results?